Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)

Market Cap	52.76B
Revenue (ttm)	3.91B
Net Income (ttm)	1.53B
Shares Out	450.00M
EPS (ttm)	3.41
PE Ratio	34.38
Forward PE	28.81
Dividend	0.80 (0.68%)
Ex-Dividend Date	Sep 10, 2025

Volume	7,175,855
Average Volume	8,234,976
Open	112.20
Previous Close	111.89
Day's Range	111.40 - 117.25
52-Week Range	39.82 - 122.20
Beta	0.53
RSI	69.52
Earnings Date	Aug 27, 2025

About SHA:688578

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China. Its lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC), as well as for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 1,417
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688578

Financial Performance

In 2024, SHA:688578's revenue was 3.56 billion, an increase of 76.29% compared to the previous year's 2.02 billion. Earnings were 1.43 billion, an increase of 121.97%.